61 results about "Immune recognition" patented technology

The present invention describes the use of nucleic acid barcodes as specific labels for MHC multimers to determine the antigen responsiveness in biological samples. After cellular selection the barcode sequence will be revealed by sequencing. This technology allows for detection of multiple (potentially >1000) different antigen-specific cells in a single sample. The technology can be used for T-cell epitope mapping, immune-recognition discovery, diagnostics tests and measuring immune reactivity after vaccination or immune-related therapies.

An immunogenic composition able to provide an immune response to Human Complement Factor H binding on one or more HIV glycoproteins is disclosed, which is characterized by at least one binding site epitope of the glycoproteins. Such immunogenic composition wherein the glycoprotein comprises gp120, gp41, or both glycoproteins gp120 and gp41 is hereby disclosed. Sialic acid is removed to enhance immune recognition of the composition and to impair Factor H binding. A medication having an inhibitive action on autoimmune response by specific inhibition of the cleavage of C3b by Factor H into inactive cell fragments.

The invention discloses a photoelectric chemical detection method of zearalenone based on a TiO2 mesocrystal. According to the method, a polydopamine-sensitized rutile type TiO2 mesocrystal is used as a photoelectric active substrate material and is applied to an immobilization zearalenone antibody; a mesoporous cobaltosic oxide marked zearalenone secondary antibody is used as a signal probe; a photoelectric chemical sensor based on a sandwich immune recognition mode is prepared by using a signal amplification effect of the probe on the substrate material and is applied to quantitative detection of zearalenone; based on stability and high conductivity of polydopamine, polydopamine and an RTM composite can accelerate transferring speed of photoinduced electrons and increasing photocurrent signals; through a sandwich immune recognition process, OMCO with competitive light-harvesting capability is introduced into a sensing interface; and high-sensitivity detection on zearalenone in a concentration range of 1x10<-6>ng/Ml-20ng/mL can be achieved.

The present invention generally concerns methods and compositions for improving the immune system of an individual that is an immune-compromised individual. In particular aspects, the immune-compromised individual is elderly or is immunosuppressed, such as from chemotherapy or immunosuppressants following organ or tissue transplantation. In specific embodiments, the invention relates to delivery to the immune-compromised individual of immune complexes harboring an antigen and an antibody that immunologically recognizes the antigen. The antigen may be viral, bacterial, or fungal, for example.

The invention provides a difunctional composite nanosphere and a method for rapidly detecting food-borne pathogenic bacteria. The difunctional composite nanosphere is characterized in that silicon dioxide is adopted and quantum dots and magnetic nanoparticles are embedded simultaneously to construct the composite nanosphere having the optical property and the superparamagetism. The corresponding quantum dot and the nanosphere are connected with a monoclonal antibody capable of specifically recognizing food-borne pathogenic bacteria, and an immune quantum dot probe capable of carrying out antigen-antibody reaction with antigens on the surface of the bacteria and an immune composite nanosphere probe are acquired. The composite nanosphere with the composite structure can be used as a carrier for immunologically recognizing and separating the pathogenic bacteria and also can be used as a signal enhancer element of the immune quantum dot probe, secondary amplification of a detection signal is realized, and target microorganisms of a sample to be detected are acquired by adopting an optical detection method. According to the method, the detection time less than or equal to 2h can be greatly shortened, the sensitivity (102cfu/mL) is improved, and the method is suitable for on-site rapid detection of foods and environment samples and can be popularized and applied in grass roots.

A method of identifying proteins in a proteome comprises the steps of: (a) immunizing a host organism with a sample containing an initial mixture of proteins from a tissue or fluid to be evaluated to elicit an antibody response to one or more proteins in the initial mixture; (b) isolating an antiserum from the host organism after immunization; (c) contacting the antiserum with an array of known proteins to form one or more antibody-protein conjugates, thereby identifying the one or more proteins in the initial mixture that elicited an antibody response in the host organism; (d) optionally removing the proteins that elicited antibody formation in step (a) from the initial mixture to form a mixture of non-responding proteins; and (e) optionally repeating the previous steps (a) through (d) one or more times, each repetition utilizing the mixture of non-responding proteins from the immediate prior repetition in place of the initial mixture of proteins to identify one or more additional proteins present in the tissue or fluid to be evaluated. A corresponding method of preparing antisera for identifying proteins in a proteome is also disclosed.

The invention relates to preparation and application of DNA vaccine that can resist to the infection of hepatitis C virus. The invention constructed a recombinant DNA vaccine that can express HCV enveloped glycoprotein E1 with molecular cloning techniques, on this basis constructed six N-glycosylation mutants M1-M6 of the E1 and select N-glycosylation mutant M2 as DNA vaccine that resist to infection of hepatitis C virus and application in the preparation of DNA vaccine that prevent the HCV virus infection. The advantages of the invention are : experiments reveal that N-sugar chain of HCV E1 enveloped glycoprotein can limit the host's cellular immune responses, its glycosylation may shield the T and B cell epitope of virus, thereby enable the virus to evade immune recognition; with E1 glycosylate mutants M2 may be used as DNA vaccines that are HCV therapeutic and preventive and enhance the immunogenicity, besides preparation of mutants M2 E1 glycosylate is simple, convenient and effective, and has good application prospect.

The invention relates to a preparation method of a photoelectrochemical immunosensor for detecting procalcitonin. Through a split-type photoelectrochemical sensor construction mode, immune recognitionanalysis and photoelectric response test analysis of an inorganic semiconductor material are separated to achieve a purpose that the photoelectric test can be realized without damaging the immune recognition process of biomolecules; a bismuth stannate nano-material modified a cadmium sulfide nano-material is used as a substrate material to provide basic photoelectric response, and band gap structures of the two are matched, so that visible light utilization efficiency can be well improved; in the antigen and antibody specific immune recognition process in a 96 microwell plate, acetylcholin esterase is firmly bound to a procalcitonin secondary antibody through an aminated aldehyde silicon dioxide material, and the compound marks the procalcitonin secondary antibody as a marker; after acetylcholine iodide is dropped into the 96-microwell plate, the acetylcholine esterase has catalytic reaction with the acetylcholine iodide to obtain a product thiocholine, which serves as an electron donor to capture holes in the material caused by light excitation, so that light current is improved to different degrees, and sensitive detection of the procalcitonin is realized; and the detection limit of the procalcitonin is 0.20 pg/mL.

The invention discloses a hapten, an artificial antigen and a monoclonal antibody for phenothiazine medicaments, preparation methods of the hapten and the artificial antigen and the application of the monoclonal antibody. The hapten contains a common structure of the phenothiazine medicaments and is connected with a carrier protein through introduced carboxyl in a preparation process of the artificial antigen for the phenothiazine medicaments, namely, the common structure is far away from the carrier protein and is completely exposed to an immunological recognition system of an animal. Therefore, a broad-spectrum specific antibody capable of recognizing a plurality of phenothiazine medicaments can be obtained when the artificial antigen is used for immunizing the animal as an immunogen, and is used for quickly realizing immunoassay and screening to improve the detection efficiency, shorten the detection time and lower the detection cost.

An antigenic and immunogenic composition of predetermined inactivated strains of human immunodeficiency virus (HIV) is disclosed. Inactivation is through psoralen and ultraviolet radiation; the composition is rendered more effective by the removal of structural features of HIV that interfere with immune response. In particular, sialic acid is removed to enhance immune recognition of the composition and to impair Complement Factor H binding. CD55 and CD59 are also removed to prevent the binding of Complement Factor H. Determination of strains for inactivation may be though immunotherapeutic genotyping or probabilistic assessment of risk of exposure.

The invention provides an immune memory learning control based wet coagulation bath temperature control process for a carbon fiber precursor. The process route is as follows: polyacrylonitrile original liquid is extruded into a coagulation bath tank through a spinneret plate, the temperature of coagulating liquid in the coagulation bath tank is subjected to real-time detection by a temperature detecting element and is fed back to a controller, the controller carries out current control quantity calculation according to the current and historical data of set value input, control quantity and feedback output and outputs a current control quantity to a controlled object, a coagulation bath is heated, and finally, the actual temperature of the coagulation bath reaches a set temperature. The controller is an intelligent temperature controller based on immune memory learning and is used for simulating an immune recognition, response and memory mechanism of a human body immune system, the traditional iterative learning control algorithms are improved, interference is taken as an antigen and is subjected to recognition, elimination and feature memory, and a control system can quickly respond and accurately control interference when the same interference occurs again, so that the stability and interference immunity of the control system are further improved.

The invention discloses a zwitterionic polypeptide, a derivative of the zwitterionic polypeptide and a nano-drug based on the zwitterionic polypeptide. Nano-drugs can be prepared on the basis of the zwitterionic polypeptide or derivatives thereof, the secondary structure of the zwitterionic polypeptide has excellent conversion capability before and after drug release, and release of the drugs in cells can be accelerated. The obtained nano-drug can be used for tumor targeted therapy; unexpected tumor targeting performance is obtained; and the nano-drug has excellent blood compatibility, has thecapability of avoiding immune recognition, tumor targeting, intracellular transformation and entering into cell nuclei, can reduce the distribution in liver, kidney, spleen, lung, heart and other organs rich in reticuloendothelial tissues, and finally realize the capability of efficiently inhibiting tumor growth and the in-vivo low-toxicity targeting tumor treatment effect.

The invention relates to a glycoprotein dynamic light scattering immunization method based on a phenylboronic acid cross-linking agent. The phenylboronic acid cross-linking agent and the magnetic carrier marked by the immune recognition element are used as a dynamic light scattering signal enhancement probe to form a multilayer sandwich structure by taking target glycoprotein as a bridge, and the average hydration kinetic particle size change of the solution before and after the multilayer sandwich structure is used as a dynamic light scattering signal to be output; and the content of glycoprotein in the to-be-detected sample is determined by utilizing the diameter change of hydration kinetics. According to the glycoprotein dynamic light scattering immunization method based on the phenylboronic acid cross-linking agent, the operation steps are simple, high-sensitivity detection of glycoprotein in a complex sample can be achieved in a short time, the prepared immunomagnetic beads can separate and enrich target protein from a complex sample matrix, and interference of the sample matrix on follow-up detection is effectively eliminated. The problem that the paired antibody is difficult to prepare can be solved, the glycoprotein can be simply, conveniently, rapidly and timely detected, and the method is worthy of being further popularized and used.

The present invention provides a mixed polypeptide vaccine, it can induce body interior to produce antibody directed against self-body several different inflammatory chemotatic factors, and it is made up by mixing hybrid peptides of different species, in which the hybrid peptide of every species is made up by covalently connecting amino tail end of fragment of specific chemotatic factor and immunological recognition fragment. The invention also provides preparation method of these products, specially adopts chemical synthetic production method and provides test method of the product. Said invented mixed vaccine is easily prepared, and is suitable for curing auto immune diseases long-term dependent on medicine.

In one example, the present invention comprises a deliberate insult or the recognition that an insult has occurred in a patient, which insult induces an immune recognition event. The T cell repertoire is catalogued from samples of the patient's lymphocytes from before and after the insult in order to detect and sequence the TCR alpha and beta loci of highly expanded T cell clonotypes. In some examples, this information is used in turn to generate autologous T cells or to create autologous genetically-engineered T cells, either of which include TCR sequences that target the individual's disease or injury, resulting in cure or amelioration of symptoms.

Particular members of the multisubunit immune recognition receptor (MIRR) family of receptors, specifically, the B cell antigen receptor (BCR), the pre-B cell receptor (pre-BCR), the pro-B cell receptor (pro-BCR), Ig Fc receptors (FcR), and NK receptors, can be physically uncoupled from their associated transducers. The invention describes regulatory compounds and methods for mimicking such dissociation/destabilization for the purposes of receptor desensitization and for treatment of conditions in which receptor desensitization or alternatively, enhanced or prolonged receptor sensitization, is desirable. Compounds and methods for enhancing or prolonging receptor sensitization are also disclosed, as are methods for identifying regulatory compounds suitable for use in the present methods.

The invention discloses a grass carp bacteria small peptide recognition receptor and a preparation method and application thereof, the grass carp bacteria small peptide recognition receptor is grass carp NOD2-LRR protein, the amino acid sequence is as shown in SEQ ID NO.1, and the cDNA sequence of the coding gene is as shown in SEQ ID NO.2. The preparation method of the grass carp bacterium small peptide recognition receptor comprises the following steps: cloning a grass carp NOD2 gene, expressing, purifying and renaturating. In the invention, an immune recognition model of grass carp NOD2 on bacterial MDP is established by using a molecular docking method for the first time, NOD2-LRR protein is successfully obtained by using a prokaryotic expression system, and the result shows that the NOD2-LRR protein has binding activity on bacterial MDP, can specifically recognize bacterial MDP, and plays an important role in immune recognition of bacterial MDP; the method has potential application value in the aspects of developing novel antibacterial agents, immunopotentiators, feed additives and the like.

The invention relates to a hepatitis B virus enrichment fluorescent PCR (polymerase chain reaction) detection method which comprises the following steps: S1, preparation of immunomagnetic beads: coupling hepatitis B virus antibodies to carboxyl modified superparamagnetic beads to obtain the immunomagnetic beads coupled with the hepatitis B virus antibodies, s2, enrichment of hepatitis B virus: mixing and incubating hepatitis B virus positive serum or plasma with the immunomagnetic beads coupled with the hepatitis B virus antibody; s3, separating the immunomagnetic bead-virus compound by using a magnetic tool, resuspending the immunomagnetic bead-virus compound in a salt ion buffer solution, and heating and cracking; and S4, separating the magnetic beads by using a magnetic tool to obtain enriched and concentrated hepatitis B virus, and directly detecting liquid in a split product by using a fluorescent PCR reagent. According to the invention, the detection sensitivity is greatly improved due to enrichment and concentration, the specificity is strong due to immune recognition and gene recognition, and the fluorescent PCR detection time is short due to the use of a rapid PCR reagent.

The invention discloses a recombinant plasmid with human cytomegalovirus UL140 gene and a genetic engineering bacterium and application thereof. The recombinant plasmid with human cytomegalovirus UL140 gene is established by inserting an UL140 gene into an expression type vector pET32a, the recombinant plasmid is further transferred into an expression bacterium BL21, then a genetic engineering bacterium for expressing a poly-histidine tag HCMV UL140 fusion protein can be established, and a corresponding HCMV UL140 fusion protein can be established through expression of the engineering bacterium. The fusion protein disclosed by the invention can be applied to affinity chromatography purification to prepare a polyclonal antibody, then the avoiding mechanism that a chemotactic factor proteinHCMV UL140 avoids a host immune system can be studied, the number of HCMV dormant infection host cells can be reduced, and the immune recognition of a body can be improved.